title: The effect of sertindole on QTD and TPTE.
abstract: OBJECTIVE
  Recent research suggests that other surrogate markers than QTc, including QTc dispersion and Tpeak-Tend, may better correlate with cardiac arrhythmia risk. While sertindole significantly prolongs the QTc interval, the effects on other markers of arrhythmia risk, such as QTc dispersion and Tpeak-Tend are unknown.
  
  
  METHODS
  Digital 12-lead ECG was recorded at baseline and at steady-state in 37 patients switched to sertindole. ECG was analysed for Fridericia-corrected QT duration (QTcF), QT dispersion and Tpeak-Tend.
  
  
  RESULTS
  From a baseline QTcF of 407 +/- 22 ms, mean QTcF prolongation during sertindole treatment was 20 +/- 23 ms, P < 0.01. No effect on QTc dispersion was found (-1 +/- 11 ms; P = 0.41). No increased duration of the Tpeak-Tend interval from baseline was found (+7 +/- 21 ms; P = 0.05).
  
  
  CONCLUSIONS
  These findings might be related to the absence of confirmed Torsade de Pointes (TdP) cases related to sertindole exposure, despite sertindole's QTc prolonging effects.
authors.affiliation: Aalborg Psychiatric Hospital, Aarhus University Hospital, Denmark. jin@rn.dk
authors.forename: J
authors.initials: J
authors.lastname: Nielsen
authors.forename: M P
authors.initials: MP
authors.lastname: Andersen
authors.forename: C
authors.initials: C
authors.lastname: Graff
authors.forename: J K
authors.initials: JK
authors.lastname: Kanters
authors.forename: T
authors.initials: T
authors.lastname: Hardahl
authors.forename: J
authors.initials: J
authors.lastname: Dybbro
authors.forename: J J
authors.initials: JJ
authors.lastname: Struijk
authors.forename: J M
authors.initials: JM
authors.lastname: Meyer
authors.forename: E
authors.initials: E
authors.lastname: Toft
mesh_terms: D000328:Adult; D014150:Antipsychotic Agents / Q000009:adverse effects* / Q000627:therapeutic use; D003718:Denmark; D004562:Electrocardiography / Q000187:drug effects*; D005260:Female; D006339:Heart Rate / Q000187:drug effects; D006801:Humans; D007093:Imidazoles / Q000009:adverse effects* / Q000627:therapeutic use; D007211:Indoles / Q000009:adverse effects* / Q000627:therapeutic use; D008133:Long QT Syndrome / Q000139:chemically induced* / Q000175:diagnosis; D008297:Male; D008875:Middle Aged; D011446:Prospective Studies; D056737:Safety-Based Drug Withdrawals; D012559:Schizophrenia / Q000188:drug therapy*; D012815:Signal Processing, Computer-Assisted; D016171:Torsades de Pointes / Q000139:chemically induced
chemical_list: D014150:Antipsychotic Agents; D007093:Imidazoles; D007211:Indoles; C066304:sertindole